Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0004134 (ataxia)
 15,886 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A patient with acute cerebellar toxicity following systemic high-dose cytosine arabinoside (ara-C) 3 g/m2/12 h for secondary acute nonlymphocytic leukemia is reported. Initial symptoms of ataxia and dysarthria emerged at 30 g/m2 cumulative dose and persisted without improvement over a ten-week period. Recurrence and worsening of cerebellar symptoms followed further consolidation treatment with high-dose ara-C. Subsequent autopsy showed extensive Purkinje's cell damage in the lateral cerebellar hemispheres. Persistent severe toxicity can occur at total doses less than those generally recognized.
 ...
PMID:Cerebellar toxicity following high-dose cytosine arabinoside. 399 79

The injection of herpes simplex virus type 1 (HSV-1) into the vitreous body of the eye in the 18 day old albino rabbits consistently induced herpes encephalitis with 90% survival. In the untreated rabbits the lesions follow a defined anatomical pathway producing a progressive disease not dissimilar to the natural human disease in that HSV travels slowly by cell-to-cell infection of neuroglia. The effects of adenine arabinoside (ara-A) and cytarabine (ara-C) on HSV encephalitis in rabbit model were studied by starting the treatment on 4th day post-inoculation of HSV. Deaths due to toxic side effects were caused by ara-A and ara-C in 30% and 50% of animals respectively, compared with 10% in untreated animals. Neurological signs, such as head jerking, ataxia and frequent epileptiform fits, occurred in ara-A, and ara-C and untreated rabbits. Comparative histological studies of optic nerves and brains showed that ara-A and ara-C had no beneficial effect, but surprisingly enhanced the disease.
 ...
PMID:Pathological findings of adenine arabinoside (ARA-A) and cytarabine (ARA-C) in the treatment of herpes simplex encephalitis in rabbit model. 628 19

A Phase II study of combined modality therapy of leptomeningeal metastases (LM) in melanoma was carried out. Central nervous system (CNS) metastases occur commonly in patients with clinically advanced melanoma. 16 patients (median age 47; range 32-62 years) with LM due to metastatic melanoma were treated. Neurologic presentation included: headache (9 patients); cranial neuropathies (6); cauda equina syndrome (4); gait ataxia (3); hemiparesis (2); radiculopathy (2); myelopathy (1); and seizure (1). All patients underwent CNS staging followed by radiotherapy (14 patients) and intraventricular chemotherapy (methotrexate 16 patients; ara-C 13 patients; thio-TEPA 7 patients). CNS imaging demonstrated: interrupted CSF flow (9 patients); parenchymal brain metastases (7); spinal cord subarachnoid nodules (5); hydrocephalus (3); and epidural spinal cord compression (2). CSF cytologic responses were seen in 4 patients to first-, 6 to second-, and 3 to third-line chemotherapy. Treatment-related toxicity included 13 patients with meningitis (12 chemical; 1 bacterial) and 12 patients (18 episodes) with myelosupression (4 episodes secondary to intraventricular chemotherapy). Median survival was 4 months (range: 2-8). Twelve patients (75%) died of progressive LM or combined LM and systemic disease progression. LM in patients with metastatic melanoma may be palliated with combined modality therapy, however, median survival is quite short suggesting a re-evaluation of such an approach in similarly affected patients.
 ...
PMID:Leptomeningeal metastases due to melanoma. 2154 42